Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.

JAMA oncology - 1 Dec 2017

Walsh Tom, Mandell Jessica B, Norquist Barbara M, Casadei Silvia, Gulsuner Suleyman, Lee Ming K, King Mary-Claire

Abstract excerpt

Importance: Among Ashkenazi Jewish women, 3 mutations in BRCA1 and BRCA2 severely increase the risk of breast and ovarian cancer. However, among Ashkenazi Jewish patients with breast cancer who do not carry one of these founder mutations, the likelihood of carrying another pathogenic mutation in BRCA1 or BRCA2 or another breast cancer gene is not known. This information would be valuable to the patient and family...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle Proteins

Share to Checkpoint Kinase 2

Share to Fanconi Anemia Complementation Group Proteins

Share to Founder Effect

Share to RNA Helicases

Source

Open in PubMed Open full text

Identifiers

PMID: 28727877
DOI: 10.1001/jamaoncol.2017.1996
PMCID: PMC5824270

Genes

BRCA1
BRCA2
CHEK2
BRIP1
NBN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.PMID 28727877Read ↗

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.Semantic proximity Read ↗

Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.Semantic proximity Read ↗

Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.Semantic proximity Read ↗

Identifying Ashkenazi Jewish <i>BRCA1/2</i> founder variants in individuals who do not self-report Jewish ancestrySemantic proximity Read ↗

Hereditary breast cancer in Jews.Semantic proximity Read ↗

Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel.Semantic proximity Read ↗

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.Semantic proximity Read ↗

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.Semantic proximity Read ↗

Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.Semantic proximity Read ↗

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.Semantic proximity Read ↗

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.Semantic proximity Read ↗

The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.